SCHEMBL761273

SCHEMBL761273

C=Cc1ccc(-c2cccnc2N(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
APP P05067 3/20 0.35
MAPT P10636 3/20 0.35
SNCA P37840 3/20 0.35
SYK P43405 1/20 0.35
METAP2 P50579 1/20 0.34
CACNA1B Q00975 1/20 0.33
MKNK1 Q9BUB5 2/20 0.33
MKNK2 Q9HBH9 2/20 0.33
TSHR P16473 2/20 0.32
F10 P00742 1/20 0.32
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
MAPK1 P28482 2/20 0.32
CLK4 Q9HAZ1 2/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5914464 0.78 KDM4E (0.46) ALDH1A1KDM4EPOLBMAPTSYK
SCHEMBL18753404 0.72 KDM4E (0.48) ALDH1A1KDM4EPOLBMAPTMETAP2
SCHEMBL20153719 0.72 KDM4E (0.37) ALDH1A1KDM4EPOLBAPPMAPT
SCHEMBL22788358 0.71 CA12 (0.55) ALDH1A1KDM4EPOLBMAPT
SCHEMBL550438 0.70 KDM4E (0.43) ALDH1A1KDM4EPOLBMAPTTSHR
SCHEMBL14715801 0.70 KDM4E (0.47) ALDH1A1KDM4EPOLBMAPTSYK
SCHEMBL941322 0.70 MKNK1 (0.42) ALDH1A1KDM4EMAPTCACNA1BMKNK1
SCHEMBL20684720 0.69 MEN1 (0.41) ALDH1A1KDM4EPOLBMKNK1MKNK2
SCHEMBL550808 0.68 ALDH1A1 (0.44) ALDH1A1MAPTTSHRMAPK1AKT1
SCHEMBL17127151 0.67 ALDH1A1 (0.42) ALDH1A1POLBCACNA1BTSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1729772-B1 HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS MERCK SHARP & DOHME (US) 2016-12-07 EP disclosed
EP-1899294-B1 THERAPEUTIC AGENTS MERCK SHARP & DOHME (GB) 2015-03-18 EP disclosed
EP-1893566-B1 CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA MERCK SHARP & DOHME (GB) 2013-02-13 EP disclosed
US-8163956-B2 Inhibitors of GLYT1 transporters MERCK SHARP & DOHME CORP. (US) 2012-04-24 US disclosed
EP-1942733-B1 RADIOLABELED GLYCINE TRANSPORTER INHIBITORS MERCK SHARP & DOHME (US) 2012-03-21 EP disclosed
US-7947714-B2 Piperidine glycine transporter inhibitors Merck, Sharp & Dohme Corp. (US) 2011-05-24 US disclosed
US-7851638-B2 Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia MERCK SHARP & DOHME LIMITED (GB) 2010-12-14 US disclosed
US-7834031-B2 Radiolabeled glycine transporter inhibitors MERCK SHARP & DOHME CORP. (US) 2010-11-16 US disclosed
US-7825135-B2 Heteroaryl piperidine glycine transporter inhibitors MERCK SHARP & DOHME LIMITED (GB) 2010-11-02 US disclosed
US-20100222317-A1 Azetidine Derivatives as GlyT1 Inhibitors MERCK SHARP & DOHME LIMITED (GB) 2010-09-02 US disclosed
US-20060281803-A1 Pyrazole modulators of metabotropic glutamate receptors MERCK & CO., INC. 2006-12-14 US disclosed
EP-1729772-A2 HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS Merck and Co., Inc. (US) 2006-12-13 EP disclosed
US-20060276655-A1 Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia MERCK SHARP & DOHME (UK) LIMITED (GB) 2006-12-07 US disclosed
US-20060235069-A1 Benzamide modulators of metabotropic glutamate receptors MERCK SHARP & DOHME CORP. 2006-10-19 US disclosed
EP-1684759-A2 4-PHENYL PIPERDINE SULFONYL GLYCINE TRANSPORTER INHIBITORS Merck & Co., Inc. (US) 2006-08-02 EP disclosed
WO-2006067529-A1 PIPERIDINE AND AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS MERCK SHARP & DOHME LIMITED (GB) 2006-06-29 WO disclosed
EP-1667983-A2 PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merck & Co., Inc. (US) 2006-06-14 EP disclosed
WO-2005094514-A2 HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS MERCK & CO., INC. (US) 2005-10-13 WO disclosed
WO-2005046601-A2 4-PHENYL PIPERDINE SULFONYL GLYCINE TRANSPORTER INHIBITORS MERCK & CO., INC. (US) 2005-05-26 WO disclosed
WO-2005030128-A2 PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK & CO., INC. (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276655-A1 Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia GLRA1, GNMT, MGAT1 ALDH1A1 1107/4885KDM4E 2863/4885POLB 4216/4885
US-20100222317-A1 Azetidine Derivatives as GlyT1 Inhibitors GRIA1, GLRA1, GRIN1 ALDH1A1 579/4885KDM4E 3744/4885POLB 4846/4885
US-20060281803-A1 Pyrazole modulators of metabotropic glutamate receptors GRM5, GRM3, GRIK5 ALDH1A1 3684/4885KDM4E 2306/4885POLB 4342/4885
US-20060235069-A1 Benzamide modulators of metabotropic glutamate receptors GRM5, GRIK5, GRM2 ALDH1A1 2695/4885KDM4E 1368/4885POLB 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.